Portola Pharmaceuticals Appoints 30-Year Industry Veteran Glenn Brame as Senior Vice President of Technical Operations
June 25 2018 - 8:30AM
Portola Pharmaceuticals, Inc.® (Nasdaq:PTLA) today announced the
appointment of Glenn Brame as senior vice president of technical
operations, effective immediately. Mr. Brame will report to Mardi
Dier, interim co-president and chief financial officer, and will be
responsible for leading the Company’s technical operations
including process development, manufacturing, supply chain, quality
assurance, and end-to-end process and platform optimization for
Portola’s entire portfolio. He will also serve as a member of
Portola’s Executive Committee, contributing directly to global
expansion efforts and related CMC activities.
“Glenn’s impressive range of global operational
expertise and leadership success will be critical to this new phase
in the Company’s trajectory, and we are pleased to welcome him to
the team,” said Ms. Dier. “His proven track record leading
manufacturing operations from the clinical phase to
commercial-scale supply will be particularly valuable as we
continue to scale up the manufacturing processes for andexanet alfa
and betrixaban.”
Prior to joining Portola, Mr. Brame was vice
president of supplier and contract manufacturing excellence for
Genentech, where he was responsible for the transformation of
quality, manufacturing, technical services and supply chain
operations for both biologics and small molecule products. During
his tenure, Mr. Brame also served as vice president of global
product quality and helped lead the successful start-up of two new
biologic manufacturing sites in Oregon and Singapore, as well as
manufacturing and quality assurance for the product approvals of
Kadcyla® and Erivedge®. Previously, Mr. Brame was senior vice
president of technical development and operations, leading a team
of 1,200 professionals for Chiron Corporation and, upon its
acquisition, Novartis.
“I am thrilled to be joining Portola at such an
exciting period of commercial evolution and growth,” said Mr.
Brame. “This is a unique opportunity to support both a strong
commercial portfolio and a promising pipeline, and I look forward
to helping this talented and scientifically innovative team achieve
its goal of delivering transformative new medicines to patients
around the world.”
About Portola Pharmaceuticals,
Inc.Portola Pharmaceuticals is a commercial-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel therapeutics that could significantly
advance the fields of thrombosis and other hematologic diseases.
The Company’s two FDA-approved medicines are
Bevyxxa® (betrixaban), the first and only oral, once-daily
Factor Xa inhibitor, and Andexxa® [coagulation factor Xa
(recombinant), inactivated-zhzo], the first and only antidote for
the Factor Xa inhibitors rivaroxaban and apixaban. The company also
is advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of
hematologic cancers.
Kadcyla and Erivedge are registered trademarks
of Genentech.
|
|
|
|
|
|
|
Investor
Contact: |
|
|
Media
Contact: |
|
|
|
Cara Miller
|
|
|
Laurie Masonson |
|
|
|
Portola
Pharmaceuticals |
|
|
Pure
Communications |
|
|
|
ir@portola.com
|
|
|
lmasonson@purecommunications.com |
|
|
|
|
|
|
|
|
|
|
Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
From Apr 2024 to May 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Historical Stock Chart
From May 2023 to May 2024